AMGN Looks 18.3% Overvalued on GF Value™
Amgen (AMGN) reported that its drug Repatha reduced mortality risk in high-risk patients, per a clinical trial. The company offers a 2.3% dividend yield with a 44% payout ratio and a 7.1% 3-year dividend growth rate. AMGN's stock trades 18.3% above its GF Value™, with a GF Score™ of 79. Insider sales totaled $29.3M over the past year, while institutional investors show mixed sentiment.
How this was made
The 30-second read
Why it matters
The mortality reduction data could expand Repatha's market share and justify higher pricing, impacting Amgen's revenue outlook.
Market read
New Phase 3 data is a catalyst for Amgen and may affect the biotech sector broadly.
What to watch
High debt‑to‑equity ratio and low momentum could limit upside despite the trial success.
Background
Amgen is a large biotech with a diversified portfolio; Repatha is a key product in its cardiovascular franchise.
Ticker impact
Amgen disclosed Phase 3 VESALIUS-CV trial results showing a 20% mortality reduction for Repatha, a new material clinical outcome.
Potential upside of 5‑10% over the next week as investors re‑price the mortality benefit.
Phase 3 mortality data is rare and materially improves the drug's value proposition, outweighing the current valuation premium.
Market effects
Strengthens the broader lipid‑lowering and cardiovascular biotech sector, potentially lifting peers.
Positive for US biotech and healthcare indices.
May influence global investors tracking cardiovascular drug pipelines.
Counterpoint
The stock is already trading at an 18% premium to intrinsic value; the price may already reflect the data.
Key entities
- companyAmgen Inc.
US‑listed biotech (NASDAQ: AMGN) reporting trial results.
- drugRepatha
Amgen's cholesterol‑lowering monoclonal antibody.
